This biotech is using the chromatin regulatory system to fight back against cancer
Foghorn Therapeutics recently announced dosing of the first patient in the Phase 1 trial of FHD-909 in collaboration with Eli Lilly.
Drug Discovery
A deep dive into one of the fastest growing biotechs of all time
Avidity Biosciences has achieved successful data readouts for all three of its programs in Phase 1/2 clinical trials, initiated its first Phase 3 trial, and raised over $1.1 billion this year.
How rationally designed therapeutics could revolutionize gene therapy
Gene therapy holds incredible promise, but the challenge has always been delivery - Affinia Therapeutics seeks to solve one of the most important problems that the industry faces.
New CEO Dr. Mike Exton has big plans for Lexicon Pharma in 2025
Lexicon has been discovering new genetic science since the Human Genome Project. Dr. Mike Exton, with over 2 decades of pharma experience, was drafted in this summer and has plans to make history.